-
公开(公告)号：KR100768632B1
公开(公告)日：2007-10-18
申请号：KR1020060105648
申请日：2006-10-30
Applicant: 삼성전자주식회사 , 재단법인서울대학교산학협력재단
CPC classification number: B22F1/0088 , B22F2998/00 , H01L51/0036 , Y10T428/268 , B22F1/0022
Abstract: A method for dispersing nanoparticles is provided to control array density of nanoparticles by adjusting pH of a charged nanoparticle dispersion, and thus form high-density nanoparticle single film without cohesion. A method for dispersing nanoparticles includes the steps of: (a) modifying the surfaces of nanoparticles to impart an electric charge to the surfaces of the nanoparticles; and (b) dispersing the surface-modified nanoparticles in a solvent and adjusting pH of the nanoparticle dispersion. A method for producing nanoparticle thin films comprises a step of arraying the pH-adjusted nanoparticle dispersion on a substrate by capillary force to prepare nanoparticle single film.
Abstract translation: 提供了一种分散纳米颗粒的方法，通过调节带电纳米粒子分散体的pH值来控制纳米颗粒的阵列密度，从而形成高密度纳米颗粒单层膜，无内聚力。 分散纳米颗粒的方法包括以下步骤：（a）改变纳米颗粒的表面以赋予纳米颗粒表面电荷; 和（b）将表面改性的纳米颗粒分散在溶剂中并调节纳米颗粒分散体的pH。 制备纳米颗粒薄膜的方法包括通过毛细管力将pH调节的纳米颗粒分散体排列在基底上以制备纳米颗粒单膜的步骤。
-
公开(公告)号：KR101121987B1
公开(公告)日：2012-03-19
申请号：KR1020080092697
申请日：2008-09-22
Applicant: 재단법인서울대학교산학협력재단
Abstract: 본 발명은 RNA 발현 벡터에 CK-B 유전자의 발현을 억제하는 siRNA를 코딩하는 뉴클레오타이드 서열을 삽입하여, 여기서 전사된 siRNA에 의해 CK-B의 발현을 억제함으로써 파골세포의 골흡수를 억제하는 벡터와 이의 응용방법에 관한 것이다. 보다 구체적으로 본 발명은 CK-B 억제 siRNA 발현 벡터, CK-B 억제 siRNA 및 이를 유효성분으로 포함하는 조성물에 관한 것으로, 액틴 링 구조 형성, RhoA의 단백질의 형성, vATPase의 활성도 및 파골세포의 골흡수를 억제하여 골대사성 질환을 예방 및 치료하는데 사용될 수 있다.
파골세포, shRNA(short hairpin RNA), siRNA(short interfering RNA), CK-B(brain-type creatine kinase)-
公开(公告)号：KR1020090117585A
公开(公告)日：2009-11-12
申请号：KR1020080092697
申请日：2008-09-22
Applicant: 재단법인서울대학교산학협력재단
Abstract: PURPOSE: A gene therapeutic agent using a siRNA expression vecor is provided to suppress actin ring structure formation, RhoA protein formation, vATPase activation, and bone resorption of osteoclast. CONSTITUTION: A CK-B gene suppression siRNA expression vector contains a promoter which starts to express siRNA(short interfering RNA) and a complementary sequence of a part of CK-B(brain-type creatine kinase) mRNA. A part of CK-B mRNA is a nucleotide of 512~532nt among CK-B mRNA sequence of the sequence number 1.
Abstract translation: 目的：提供使用siRNA表达vecor的基因治疗剂，以抑制肌动蛋白环结构形成，RhoA蛋白形成，vATPase活化和破骨细胞的骨吸收。 构成：CK-B基因抑制siRNA表达载体含有开始表达siRNA（短干扰RNA）的启动子和部分CK-B（脑型肌酸激酶）mRNA的互补序列。 CK-B mRNA的一部分是序列号1的CK-B mRNA序列中的512〜532nt的核苷酸。
-
-
Search Results
3
records
(took 0.021 seconds)
